Finger RP, Puth MT, Schmid M, et al. - In this multistate model using real-world data, researchers sought to determine visual acuity (VA) outcomes of anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (nAMD) in both eyes for patients’ remaining lifetime. The sample consisted of 3,192 patients with nAMD (> 67,000 visits) treated in routine eye clinics in Australia, New Zealand, and Switzerland. Between 2007 and 2015, data were analyzed. The anti-VEGF treatment has been linked to preserved useful visual acuity in almost 20% of patients over their average remaining lifetime. During that time, more than 80% of patients would stop treatment, having probably undergone a deterioration in vision beforehand. Compared with outcomes without intervention, this is a remarkable result, leading to legal blindness in 80% of those affected within 3 years of the onset of the disease. Such results underscore the public health necessity of providing anti-VEGF treatment to persons in need.